Adial Pharmaceuticals
ADIL
15 hedge funds and large institutions have $328K invested in Adial Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
39% more capital invested
Capital invested by funds: $236K → $328K (+$91.8K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
0.16% less ownership
Funds ownership: 0.43% → 0.27% (-0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$118K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$37.4K |
| 4 |
BlackRock
New York
|
+$30.4K |
| 5 |
1IA
1620 Investment Advisors
Plymouth,
Massachusetts
|
+$5.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$27K |
| 2 |
Renaissance Technologies
New York
|
-$25.3K |
| 3 |
HF
HRT Financial
New York
|
-$9.91K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.33K |
| 5 |
HT
Headlands Technologies
Chicago,
Illinois
|
-$85 |
ADIL Hedge Fund Activity: Q2 2024 in Review
15 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2024, worth a combined $328K — up 39% from $236K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ADIL positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $118K. The largest seller was Virtu Financial, exiting entirely with an estimated $27K sold.
- 15 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2024, up from 14 in Q1 2024.
- Funds reported $328K of Adial Pharmaceuticals stock for Q2 2024, up 39% quarter-over-quarter.
- 4 funds opened new Adial Pharmaceuticals positions in Q2 2024 and 3 closed out, a net change of +1 holder.
- The largest Adial Pharmaceuticals buyer in Q2 2024 was UBS Group, an estimated $118K added.
- The largest Adial Pharmaceuticals seller in Q2 2024 was Virtu Financial, an estimated $27K sold.
Based on aggregated 13F filings for Q2 2024.